Financhill
Buy
66

BDUUF Quote, Financials, Valuation and Earnings

Last price:
$0.66
Seasonality move :
3.46%
Day range:
$0.66 - $0.66
52-week range:
$0.64 - $0.80
Dividend yield:
3.37%
P/E ratio:
22.90x
P/S ratio:
3.42x
P/B ratio:
3.58x
Volume:
--
Avg. volume:
750
1-year change:
-12.19%
Market cap:
$10.5B
Revenue:
$3.1B
EPS (TTM):
$0.03

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Bangkok Dusit Medical Services PCL has -- downside to fair value with a price target of -- per share.

BDUUF vs. S&P 500

  • Over the past 5 trading days, Bangkok Dusit Medical Services PCL has underperformed the S&P 500 by -3.68% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Bangkok Dusit Medical Services PCL does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Bangkok Dusit Medical Services PCL has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Bangkok Dusit Medical Services PCL reported revenues of $805.5M.

Earnings Growth

  • Bangkok Dusit Medical Services PCL has grown year-over-year earnings for 7 quarters straight. In the most recent quarter Bangkok Dusit Medical Services PCL reported earnings per share of $0.01.
Enterprise value:
10.6B
EV / Invested capital:
--
Price / LTM sales:
3.42x
EV / EBIT:
18.03x
EV / Revenue:
3.48x
PEG ratio (5yr expected):
1.95x
EV / Free cash flow:
33.29x
Price / Operating cash flow:
32.77x
Enterprise value / EBITDA:
13.93x
Gross Profit (TTM):
$1.1B
Return On Assets:
10.85%
Net Income Margin (TTM):
14.85%
Return On Equity:
15.75%
Return On Invested Capital:
14.33%
Operating Margin:
19.39%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $2.6B $2.9B $3.1B $736.3M $805.5M
Gross Profit $959.3M $1.1B $1.1B $278.3M $304.7M
Operating Income $485.5M $541.6M $581.4M $143.8M $156.2M
EBITDA $659.2M $718.2M $764.3M $188.4M $205.5M
Diluted EPS $0.02 $0.03 $0.03 $0.01 $0.01
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $1B $731.5M $803.7M $645.3M $692.1M
Total Assets $4.5B $3.9B $4.1B $3.9B $4.4B
Current Liabilities $374.8M $475.5M $596M $505.2M $644M
Total Liabilities $1.5B $1.2B $1.4B $1.2B $1.4B
Total Equity $3.1B $2.6B $2.7B $2.7B $3B
Total Debt $694.3M $469.8M $463.4M $287.7M $307.1M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $579.2M $597.6M $651M $120.8M $113.9M
Cash From Investing -$168.7M -$222.4M -$322.8M -$66.6M -$121.6M
Cash From Financing -$361M -$513.4M -$339.4M -$66.2M -$41.3M
Free Cash Flow $434.3M $359.3M $319.8M $54.2M $11.1M
BDUUF
Sector
Market Cap
$10.5B
$36.4M
Price % of 52-Week High
82.56%
44.05%
Dividend Yield
3.37%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-12.19%
-39.12%
Beta (5-Year)
0.413
0.742
Dividend yield:
3.37%
Annualized payout:
$0.02
Payout ratio:
69.36%
Growth streak:
2 years

Technicals

8-day SMA
Sell
Level $0.66
200-day SMA
Sell
Level $0.74
Bollinger Bands (100)
Sell
Level 0.65 - 0.77
Chaikin Money Flow
Sell
Level -1.2M
20-day SMA
Sell
Level $0.66
Relative Strength Index (RSI14)
Buy
Level 53.76
ADX Line
Sell
Level 47.92
Williams %R
Sell
Level 0
50-day SMA
Sell
Level $0.66
MACD (12, 26)
Sell
Level 0.00
25-day Aroon Oscillator
Sell
Level 0
On Balance Volume
Sell
Level -1M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (6.9659)
Buy
CA Score (Annual)
Level (1.1989)
Buy
Beneish M-Score (Annual)
Level (-2.5524)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-2.2973)
Buy
Piotroski F Score (Annual)
Level (7)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Bangkok Dusit Medical Services PCL operates a network of hospitals throughout Thailand under the Bangkok Hospital, Phyathai Hospital, Samitivej Hospital, Paolo Hospital, BNH Hospital, and Royal International Hospital brands. In addition to the firm's core hospital business, it operates a variety of other businesses. The other businesses support the hospital business and include a medical laboratory and manufacture and distribution of medicine and pharmaceutical products. Bangkok Dusit's hospital operations generate the vast majority of its revenue.

Stock Forecast FAQ

In the current month, BDUUF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BDUUF average analyst price target in the past 3 months is --.

  • Where Will Bangkok Dusit Medical Services PCL Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Bangkok Dusit Medical Services PCL share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Bangkok Dusit Medical Services PCL?

    Analysts are divided on their view about Bangkok Dusit Medical Services PCL share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bangkok Dusit Medical Services PCL is a Sell and believe this share price will rise from its current level to --.

  • What Is Bangkok Dusit Medical Services PCL's Price Target?

    The price target for Bangkok Dusit Medical Services PCL over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is BDUUF A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Bangkok Dusit Medical Services PCL is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of BDUUF?

    You can purchase shares of Bangkok Dusit Medical Services PCL via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bangkok Dusit Medical Services PCL shares.

  • What Is The Bangkok Dusit Medical Services PCL Share Price Today?

    Bangkok Dusit Medical Services PCL was last trading at $0.66 per share. This represents the most recent stock quote for Bangkok Dusit Medical Services PCL. Yesterday, Bangkok Dusit Medical Services PCL closed at $0.66 per share.

  • How To Buy Bangkok Dusit Medical Services PCL Stock Online?

    In order to purchase Bangkok Dusit Medical Services PCL stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Bill Ackman Buy Uber Stock?
Why Did Bill Ackman Buy Uber Stock?

In February, Pershing Square manager Bill Ackman revealed that his…

Should You Buy Alibaba Stock Despite the Risks?
Should You Buy Alibaba Stock Despite the Risks?

Markets rebounded slightly after U.S. President Donald Trump announced a…

Why Is Intel Struggling Against AMD?
Why Is Intel Struggling Against AMD?

Due to its disappointing reports, so-so management, and lack of…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
54
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $2.6T
P/E Ratio: 36x

Alerts

Sell
48
FI alert for Apr 25

Fiserv [FI] is up 1.1% over the past day.

Buy
66
FARO alert for Apr 25

Faro Technologies [FARO] is up 0.35% over the past day.

Buy
55
PI alert for Apr 25

Impinj [PI] is up 0.78% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock